Thomas W. Dubensky

Thomas W. Dubensky

Company: Tempest Therapeutics

Job title: President

Seminars:

Systemic Small Molecule TREX1 Inhibitors to Selectively Activate STING in the TME of Metastatic Disease 12:00 pm

Although STING is a critical innate immune receptor, the clinical activity of STING agonists given by intratumoral administration has not compared well to preclinical studies TREX1 is a cytosolic dsDNA exonuclease that modulates the cGAS/STING pathway activation, is a DNA repair enzyme, is upregulated in tumors, and is a target to preferentially activate the STING…Read more

day: Day One

Breakfast Panel Discussion: How Far Have We Come & Where Do We Want to Go? 9:30 am

Dissecting the recent advances in PRR-targeting drugs Sharing insights into the directions for more successful immune system manipulation Thoughts on modes of action being investigated, conclusions drawn from setbacks and ways to improve the clinical outcomes Pathway understanding, indications, toxicity outlooks, combinations, drug formats and delivery mechanisms Biological understanding update: pathway, biomarker and translational updates…Read more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.